Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

4D MOLECULAR THERAPEUTICS, INC.

(FDMT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

4D Molecular Therapeutics, Inc.(NasdaqGS:FDMT) added to Russell 3000E Value Index

06/25/2021 | 12:00am EDT

4D Molecular Therapeutics, Inc.(NasdaqGS:FDMT) added to Russell 3000E Value Index


ę S&P Capital IQ 2021
All news about 4D MOLECULAR THERAPEUTICS, INC.
09/244D MOLECULAR THERAPEUTICS INC. : Change in Directors or Principal Officers, Financial Stat..
AQ
09/244D Molecular Therapeutics Announces Late-Breaking Presentation of 4D-125 Clinical Data ..
GL
08/124D MOLECULAR THERAPEUTICS : Reports Financial Results for the Second Quarter of 2021 and P..
PU
08/124D MOLECULAR THERAPEUTICS : Management's Discussion and Analysis of Financial Condition an..
AQ
08/124D MOLECULAR THERAPEUTICS INC. : Results of Operations and Financial Condition, Financial ..
AQ
08/124D MOLECULAR THERAPEUTICS : Earnings Flash (FDMT) 4D MOLECULAR THERAPEUTICS Reports Q2 Rev..
MT
08/124D MOLECULAR THERAPEUTICS : Reports Financial Results for the Second Quarter of 2021 and P..
AQ
08/124D Molecular Therapeutics, Inc. Announces Unaudited Earnings Results for the Second Qua..
CI
08/124D Molecular Therapeutics, Inc. Appoints Nadine Greiner as Chief Human Resources Office..
CI
06/254D MOLECULAR THERAPEUTICS INC. : Termination of a Material Definitive Agreement, Other Eve..
AQ
More news
Analyst Recommendations on 4D MOLECULAR THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 16,9 M - -
Net income 2021 -71,0 M - -
Net cash 2021 196 M - -
P/E ratio 2021 -13,7x
Yield 2021 -
Capitalization 949 M 949 M -
EV / Sales 2021 44,5x
EV / Sales 2022 281x
Nbr of Employees 104
Free-Float 76,9%
Chart 4D MOLECULAR THERAPEUTICS, INC.
Duration : Period :
4D Molecular Therapeutics, Inc. Technical Analysis Chart | FDMT | US35104E1001 | MarketScreener
Technical analysis trends 4D MOLECULAR THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 35,18 $
Average target price 50,00 $
Spread / Average Target 42,1%
EPS Revisions
Managers and Directors
David H. Kirn President, Chief Executive Officer & Director
August J. Moretti Chief Financial Officer
John F. Milligan Executive Chairman
Melissa Kotterman Vice President-Discovery & Engineering
Fred Kamal Chief Operating & Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
4D MOLECULAR THERAPEUTICS, INC.-15.13%949
MODERNA, INC.311.74%183 498
LONZA GROUP AG33.58%61 085
IQVIA HOLDINGS INC.46.01%50 254
CELLTRION, INC.-23.54%33 124
SEAGEN INC.-7.88%30 241